Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update
Top Cited Papers
Open Access
- 31 August 2017
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 102 (3), 397-404
- https://doi.org/10.1002/cpt.668
Abstract
This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing. Evidence from the published literature is presented for CYP2C9, VKORC1, CYP4F2, and rs12777823 genotype-guided warfarin dosing to achieve a target international normalized ratio of 2-3 when clinical genotype results are available. In addition, this updated guideline incorporates recommendations for adult and pediatric patients that are specific to continental ancestry.Funding Information
- National Institutes of Health (R24GM115264, R24GM61374, U01 GM074492, U01 HG 007269, K23GM104401, GM109145, R01HL092173, K24HL133373, R01 HL097036)
- Swedish Research Council (Medicine 521‐2011‐2440, 521‐2014‐3370)
This publication has 44 references indexed in Scilit:
- Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association studyThe Lancet, 2013
- Warfarin dose prediction in children using pharmacometric bridging—comparison with published pharmacogenetic dosing algorithmsEuropean Journal of Clinical Pharmacology, 2013
- Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study designThe Pharmacogenomics Journal, 2011
- Genetic Warfarin Dosing: Tables Versus AlgorithmsJournal of the American College of Cardiology, 2011
- CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research NetworkClinical Pharmacology & Therapeutics, 2011
- Integration of Genetic, Clinical, and INR Data to Refine Warfarin DosingClinical Pharmacology & Therapeutics, 2010
- CYP4F2 Is a Vitamin K1 Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M VariantMolecular Pharmacology, 2009
- Estimation of the Warfarin Dose with Clinical and Pharmacogenetic DataThe New England Journal of Medicine, 2009
- Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinClinical Pharmacology & Therapeutics, 2008
- Warfarin Pharmacogenetics: CYP2C9 and VKORC1 Genotypes Predict Different Sensitivity and Resistance Frequencies in the Ashkenazi and Sephardi Jewish PopulationsAmerican Journal of Human Genetics, 2008